Study Finds GLP-1 Drugs Associated with 58% Lower Mortality in Colon Cancer Patients
By
gmays
6mo ago· 5 min readenNews
92/100
Golden Brown
Bagelometer↗
Toasted golden, schmeared with insight. Top of the rack.
Score92TypenewsSentimentpositive
Summary
A study analyzing over 6,800 colon cancer patients across University of California Health sites found that patients taking GLP-1 medications (like Ozempic and Wegovy) were less than half as likely to die within five years compared to those not on the drugs (15.5% vs. 37.1%). The research suggests these diabetes and weight-loss drugs may have significant anti-cancer effects beyond their primary metabolic benefits, potentially offering new treatment avenues for colon cancer patients.
Key quotes
· 3 pulledColon cancer patients taking GLP-1 medications were less than half as likely to die within five years compared to those who weren't on the drugs (15.5% vs. 37.1%)
In an analysis of more than 6,800 colon cancer patients across all University of California Health sites, researchers found that those taking glucagon-like peptide-1 (GLP-1) medications were less than half as likely to die within five years
The dramatic difference in mortality rates suggests GLP-1 drugs may have significant anti-cancer effects beyond their primary metabolic benefits
In an analysis of more than 6,800 colon cancer patients across all University of California Health sites, researchers found that those taking glucagon-like peptide-1 (GLP-1) medications were less than half as likely to die within five years compared to th
